Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?

Bio-Rad Laboratories, Inc.'s (BIO) growth in the upcoming quarters is likely to be backed by its Digital PCR business, which boasts a strong pipeline. The company's Clinical Diagnostics arm is seeing increased demand for quality control, blood typing and diabetes products. Sound financial stability also appears encouraging. However, the impact of macroeconomic challenges on Bio-Rad's operations poses a concern. Persistent reduced demand in the Biopharma segment adds to the worry. Let's delve deeper. Image S ...